Jiangsu Hengrui Medicine (600276.SS) Earnings
Price: $49.60
Market Cap: $314.93B
Market Cap: $314.93B
Revenue (TTM): $27.98B
Net Income: $6.34B
Net Income: $6.34B
P/E Ratio: 45.29
EPS (TTM): $1.10
EPS (TTM): $1.10
Earnings Dates
Jiangsu Hengrui Medicine (600276.SS) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: August 20, 2025
- Time of Day: Before Market Open
- Estimated EPS: $N/A
Last Earnings Report
- Date: April 24, 2025
- EPS: $0.29
- EPS Estimate: $0.03651
Jiangsu Hengrui Medicine 's next earnings report is scheduled for August 20, 2025.
In its last earnings report on April 24, 2025, Jiangsu Hengrui Medicine reported earnings per share (EPS) of $0.29, compared to an estimated EPS of $0.04. The company reported revenue of $7.21B, compared to an estimated revenue of $992.59M.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| April 24, 2025 | $0.29 | $0.04 | $7.21B | $992.59M |
| April 16, 2025 | $0.27 | $0.35 | $7.80B | $- |
| October 24, 2024 | $0.19 | $0.23 | $6.59B | $933.55M |
| August 21, 2024 | $0.33 | $0.33 | $7.55B | $1.01B |
| April 26, 2024 | $0.21 | $0.20 | $6.00B | $6.25B |
| April 17, 2024 | $0.14 | $0.17 | $5.81B | $831.78M |
| October 25, 2023 | $0.18 | $0.21 | $5.85B | $6.23B |
| August 18, 2023 | $0.17 | $0.18 | $5.68B | $6.70B |
| May 30, 2023 | $0.19 | $0.19 | $5.49B | $5.59B |
| April 21, 2023 | $0.19 | $0.19 | $5.33B | $5.59B |
| October 28, 2022 | $0.17 | $0.18 | $5.72B | $5.92B |
| August 19, 2022 | $0.14 | $0.20 | $4.75B | $5.22B |
| April 22, 2022 | $0.05 | $0.30 | $5.71B | $7.17B |
| March 30, 2022 | $0.19 | $ | $5.48B | $- |
| October 19, 2021 | $0.24 | $0.30 | $6.90B | $8.63B |
| August 19, 2021 | $0.19 | $0.27 | $6.37B | $- |
| April 20, 2021 | $0.23 | $0.21 | $8.32B | $- |
| March 30, 2021 | $0.23 | $ | $6.93B | $- |
Annual Earnings
Annual Revenue
$27.98B
Fiscal Year 2024Annual Net Income
$6.34B
Fiscal Year 2024Annual EPS
$1.00
Fiscal Year 2024Quarterly Earnings
Revenue
$7.21B
Quarter Ending March 31, 2025Net Income
$1.87B
Quarter Ending March 31, 2025EPS
$0.30
Quarter Ending March 31, 2025Earnings Metrics
Earnings Yield
2.18%
Year Ending December 31, 2024P/E Ratio
45.90
Year Ending December 31, 2024Revenue Per Share
$4.42
Year Ending December 31, 2024Earnings Yield (TTM)
2.21%
Trailing Twelve MonthsP/E Ratio (TTM)
45.29
Trailing Twelve MonthsRevenue Per Share (TTM)
$4.66
Trailing Twelve MonthsFrequently Asked Questions
Jiangsu Hengrui Medicine 's next earnings date is scheduled for August 20, 2025. The earnings call is expected to take place before market open.
In its last earnings report on April 24, 2025, Jiangsu Hengrui Medicine reported earnings per share (EPS) of $0.29, compared to an estimated EPS of $0.04. The company reported revenue of $7.21B, compared to an estimated revenue of $992.59M.
Jiangsu Hengrui Medicine 's current Price-to-Earnings (P/E) ratio is 45.90. The trailing twelve months (TTM) P/E ratio is 45.29. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Jiangsu Hengrui Medicine reported total revenue of $27.98B and net income of $6.34B. This represents a net profit margin of 0.226429029.
Jiangsu Hengrui Medicine 's earnings yield is 2.18%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Jiangsu Hengrui Medicine 's return on equity (ROE) is 13.92%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Jiangsu Hengrui Medicine 's gross profit margin is 86.25%. This indicates that for every dollar of revenue, the company retains $0.86 as gross profit after accounting for the cost of goods sold.